Status:
NOT_YET_RECRUITING
Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
The Affiliated Hospital of Qingdao University
Shandong Provincial Hospital
Conditions:
Urinary Bladder Neoplasms
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This randomized, double-blind, placebo-controlled, multicenter trial evaluates the efficacy and safety of Antarctic krill oil in reducing side effects of intravesical therapy for non-muscle-invasive b...
Detailed Description
This randomized, double-blind, placebo-controlled, multicenter clinical trial aims to evaluate the efficacy and safety of Antarctic krill oil functional food in alleviating side effects of intravesica...
Eligibility Criteria
Inclusion
- 1\. Diagnosed bladder cancer: The patient needs to be diagnosed with bladder cancer through pathological examination and have undergone bladder cancer surgery.
- 2\. Planned to receive bladder infusion therapy: Patients need to plan to receive bladder infusion therapy after surgery and agree to participate in the study.
- 3\. Age range: 18 to 75 years old.
- 4\. Normal blood, liver and kidney function: Laboratory tests showed that the patient's blood routine, liver function and kidney function were within the normal range.
- 5\. Signed informed consent: The patient understands the content of the study and voluntarily signs the informed consent.
Exclusion
- 1\. Serious comorbidities: including but not limited to heart disease, severe liver and kidney insufficiency, uncontrolled hypertension, diabetes, etc.
- 2\. History of allergies: Patients with a known history of allergy to krill oil or perfusion drug components.
- 3\. History of prior chemotherapy: Patients who have received perfusion therapy prior to this study.
- 4\. History of other malignant tumors: Patients with a history of other malignant tumors.
- 5\. Pregnancy or lactation: Female patients who are pregnant or lactating.
- 6\. Psychiatric illness: Patients with a history of severe psychiatric illness or currently receiving treatment for psychiatric illness.
- 7\. Poor study compliance: Patients who believe that they are unable to complete the entire trial process as required by the study.
- 8\. Other: Other conditions that the investigator considers unsuitable to participate in this study.
Key Trial Info
Start Date :
July 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2028
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT06880939
Start Date
July 15 2025
End Date
May 30 2028
Last Update
July 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250000